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Summary
 
TRANCE (tumor necrosis factor–related activation-induced cytokine) is a recently described
member of the tumor necrosis factor superfamily that stimulates dendritic cell survival and has
also been found to induce osteoclastic differentiation from hemopoietic precursors. However,
its effects on mature osteoclasts have not been defined. It has long been recognized that stimu-
lation of osteoclasts by agents such as parathyroid hormone (PTH) occurs through a hormonal
interaction with osteoblastic cells, which are thereby induced to activate osteoclasts. To deter-
mine whether TRANCE accounts for this activity, we tested its effects on mature osteoclasts.
TRANCE rapidly induced a dramatic change in osteoclast motility and spreading and inhibited
apoptosis. In populations of osteoclasts that were unresponsive to PTH, TRANCE caused acti-
vation of bone resorption equivalent to that induced by PTH in the presence of osteoblastic
cells. Moreover, osteoblast-mediated stimulation of bone resorption was abrogated by soluble
TRANCE receptor and by the soluble decoy receptor osteoprotegerin (OPG), and stimulation
of isolated osteoclasts by TRANCE was neutralized by OPG. Thus, TRANCE expression by
osteoblasts appears to be both necessary and sufficient for hormone-mediated activation of ma-
ture osteoclasts, and TRANCE-R is likely to be a receptor for signal transduction for activa-
tion of the osteoclast and its survival.
Key words: osteoblast • osteoclast • TRANCE • bone resorption • parathyroid hormone
 
B
 
one resorption, a function unique to the osteoclast, is
regulated at several levels. Although supply from he-
mopoietic precursors sustains osteoclast numbers, regulation
of mature cells also occurs, as evidenced by the rapid mor-
phologic and calcemic responses that precede changes in os-
teoclast numbers when calciotropic hormones such as par-
athyroid hormone (PTH) and calcitonin are administered
systemically. It has been known for many years that cells of
the osteoblastic lineage play a crucial role in this process, such
that agents like PTH, which stimulate resorption, do so by
inducing osteoblastic cells to stimulate osteoclasts (1, 2). The
molecular basis for this stimulation has remained elusive.
Recently, TRANCE (TNF-related activation induced
cytokine) and its receptor (TRANCE-R; also called RANK)
were identified in T and dendritic cells, respectively, as
novel members of the TNF/TNFR superfamily (3–5). The
same ligand was independently identified in bone marrow
stromal cells and shown to induce the differentiation of he-
mopoietic progenitors into osteoclasts (6). Consistent with
a role in osteoclastogenesis, the ligand was upregulated in
osteoblasts incubated in calciotropic hormones. Lacey et al.
(7) also identified TRANCE as an osteoblast-expressed
ligand that stimulates osteoclastic differentiation and bone
resorption. TRANCE-induced osteoclast formation and
resorption were shown to be inhibited by osteoprotegerin
(OPG), a soluble member of the TNFR superfamily en-
coded by a different gene from that for TRANCE-R.
TRANCE thus clearly induces osteoclastic differentiation
from immature precursors. However, the effects of TRANCE
on mature osteoclasts, and in particular the question whether
TRANCE can by itself account for the action of osteoblastic
cells on mature osteoclasts, or whether osteoblastic cofactors
are also required, are questions that have not been addressed.
We therefore assessed the effects of TRANCE on the motil-
ity, cytoplasmic spreading, survival, and bone resorptive ac-
tivity of mature osteoclasts isolated from neonatal rat bone.
 
Materials and Methods
 
Recombinant soluble TRANCE (hCD8-TRANCE), in which
the extracellular domain of murine TRANCE (amino acids 245–
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316) was fused to human CD8
 
a
 
 (amino acids 1–182), was pre-
pared as previously described (3, 4). hCD8-TRANCE was puri-
fied on cyanogen bromide–activated Sepharose gel conjugated to
OKT8 following the manufacturer’s protocol (Amersham Phar-
macia Biotech, Piscataway, NJ). TRANCE receptor-Fc, a re-
combinant protein of the extracellular domain of TRANCE-R
(also called RANK; reference 5) fused to the constant region of
human IgG1, was prepared in a similar way using a baculovirus
system. Recombinant human M-CSF was provided by Dr. J.
Wozney (Genetics Institute, Cambridge, MA). Bovine PTH (1-
34), used at 0.1 U/ml throughout, was purchased from Sigma
Chemical Co. (Poole, UK). 1,25(OH)
 
2
 
vitamin D
 
3
 
 (used at 10
 
2
 
8
 
M), was provided by Solvay Duphar (Weesp, The Netherlands).
OPG was provided by Dr. C. Dunstan (Amgen, Thousand Oaks,
CA). Osteoblast-like UMR 106 cells were from Dr. T.J. Martin
(St. Vincents Institute for Medical Research, Melbourne, Australia).
Slices of bovine cortical bone were employed as substrates for
osteoclastic resorption. Bone slices (4 
 
3 
 
3 
 
3 
 
0.1 mm) were pre-
pared from adult bovine femora by using a low-speed saw
(Isomet Corp., Springfield, VA), as previously described (8),
cleaned by ultrasonication, washed, and stored dry at room tem-
perature.
 
Assessment of Bone Resorption by Mature Osteoclasts.
 
Osteoclasts
were disaggregated, as previously described, from neonatal rat
long bones (8). Wistar rats from the St. George’s Medical School
colony were killed by cervical dislocation within 72 h of birth.
The femora, tibiae, and humeri were removed and dissected free
of adherent tissue. Bones were then cut across their epiphyses and
curetted in medium 199, and the curettings were vigorously agi-
tated with a plastic pipette. Large fragments were allowed to sedi-
ment for 10 s. The cell suspension was then transferred to a 100 
 
3
 
18 mm multiwell dish (Sterilin, Teddington, UK) containing
bone slices. After 15 min of sedimentation, the bone slices were
removed, washed in medium 199, and incubated overnight in a
96-well tissue culture plate (Sterilin) in the presence or absence of
hCD8-TRANCE, TRANCE-R, OPG, and/or calciotropic hor-
mones. For some experiments osteoclasts were co-cultured with
either UMR 106 (5 
 
3 
 
10
 
4
 
 cells/well) or calvarial cells (10
 
4
 
 cells/
well). To prepare calvarial cells, calvarias were removed from rats
within 5 d of birth, dissected free of soft tissues and periosteum,
and incubated for 2 h at 37
 
8
 
C in collagenase (type II; Sigma
Chemical Co.; 1 mg/ml in medium 199). The bones were then
vigorously agitated with a plastic pasteur pipette and the cell sus-
pension was harvested. The cells were washed and resuspended in
Hanks’ MEM for addition to osteoclasts on bone slices. For all exper-
iments, the final volume of incubation medium per well was 200 
 
m
 
l.
Bone resorption was assessed after 18 h of incubation, as previ-
ously described (9). Bone slices were removed from wells, im-
mersed in 10% NaCl (BDH, Poole, UK) for 10 min to remove
cells, washed in distilled water, dried, and sputter coated with
gold. The entire surface of each bone slice was then examined in
a scanning electron microscope (S90; Cambridge Instruments,
Cambridge, UK).
 
Survival Studies.
 
Bone cell suspensions were added to the
wells of a 96-well plate (Sterilin) containing Thermanox cover-
slips (Gibco, Uxbridge, UK) and incubated for 15 min. Cover-
slips were then removed, washed in PBS, and placed into individ-
ual wells of a 96-well plate. Cells were incubated for 1 or 24 h in
a total volume of 200 
 
m
 
l MEM/BSA in the presence of hCD8-
TRANCE, M-CSF, or vehicle. Cells were then fixed for 2 min
in formalin and stained for tartrate-resistant acid phosphatase
(TRAP) (10). The substrate used was naphthol AS-B1 phosphate.
Tartrate resistance was assessed in the presence of 0.05 M sodium
tartrate. TRAP-positive multinuclear cells were counted by light
microscopy.
 
Time-Lapse Observations.
 
The bone cell suspension, obtained
as above, was added to 25-cm
 
2
 
 tissue culture flasks (Sterilin) and
incubated for 15 min to allow osteoclast sedimentation and at-
tachment. Nonadherent and loosely adherent cells were removed
by washing with PBS. 10 ml of MEM/BSA were placed into the
flasks and the cells were incubated for 30 min. Flasks were then
sealed and placed in the incubation chamber of an Olympus
1MT-373 inverted microscope (Gallenkamp & Co. Ltd., Lon-
don, UK). A suitable osteoclast-containing field was chosen and
recorded for 30 min on a time-lapse video recorder at 1/60 nor-
mal speed. Vehicle or hCD8-TRANCE was then added in 0.5 ml
prewarmed MEM/BSA and recording continued.
 
Measurement of Osteoclast Spread Area.
 
Osteoclasts were incu-
bated on Thermanox coverslips as above in the presence of
M-CSF, hCD8-TRANCE, or vehicle for 1 h. Then, they were
fixed and stained for TRAP activity. Osteoclast spread area was
determined with a light microscope linked to a computer-assisted
image analyzer (Perceptive Instruments, Cambridge, UK).
 
Results and Discussion
 
Addition of recombinant soluble TRANCE (hCD8-
TRANCE) to isolated osteoclasts caused a dramatic change
in their behavior. Within minutes the osteoclasts showed
increased pseudopodial motility, associated with increased
cell spreading (Fig. 1). Unlike M-CSF, which induces ex-
tension of cytoplasm around much or all of the periphery
(9), osteoclastic motility and spreading remained localized
in broad focal pseudopods, and was associated with rhyth-
mic contractions of the cell body, similar to those we have
occasionally observed to occur “spontaneously” in previous
time-lapse studies of these cells (our unpublished data). Os-
teoclastic spreading has previously been noted in response
to PTH, and was found to be dependent upon the presence
of osteoblastic cells (11).
Isolated osteoclasts rapidly undergo apoptosis in vitro
 
,
 
which can be suppressed by M-CSF (9). However, the ex-
istence of alternative osteoblast-derived survival factors was
suggested by the ability of osteoblastic cells from 
 
op/op
 
mice, which lack M-CSF, to support survival of osteoclasts
(our unpublished data), and by the prolonged resorption of
bone that occurs after even a single administration of
M-CSF to these mutants (12). hCD8-TRANCE stimu-
lated osteoclastic survival at 100 and 1,000 ng/ml, similar
to the concentrations that support dendritic cell survival (4)
(Fig. 1). The relatively high concentration of the soluble
ligand needed might reflect a physiological presentation of
the ligand as a cell surface molecule (3, 5, 6). A previous
study (7) found no effect of TRANCE in the survival of
mature osteoclasts. However, no zero time point was in-
cluded, so that the possibility was not excluded that suffi-
cient levels of TRANCE or M-CSF, an alternative osteo-
clast survival factor (9), were generated by contaminant
bone cells, for survival to occur in the absence of exoge-
nous TRANCE.
We then tested the ability of hCD8-TRANCE to stim-
ulate bone resorption by isolated osteoclasts. The con- 
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founding influence of TRANCE on osteoclast survival was
avoided by adding M-CSF to all cultures. We found that in
populations of osteoclasts isolated from neonatal rat bone
under conditions that render them unresponsive to PTH
(i.e., in cultures lacking the ability to generate detectable
levels of osteoclast resorption stimulating activity), hCD8-
TRANCE induced dose-responsive stimulation of bone
resorption (Fig. 2). TRANCE is the first agent found to be
capable of stimulating bone resorption in this system, with-
out added osteoblasts, in cultures that are unresponsive to
indirect acting agents, such as PTH. Similar results were re-
ported by Lacey et al. (7). However, in that report no con-
trol cultures incubated with an indirect-acting calciotropic
hormone were included, so that the extent to which con-
taminant osteoblasts contributed to or mediated this re-
sponse could not be determined. The very rapid motile re-
sponses seen in isolated osteoclasts, and the increase in bone
resorption by hCD8-TRANCE in cultures unable to gen-
erate endogenous osteoclast-stimulating activity, suggest
that hCD8-TRANCE directly stimulates osteoclasts. Like
the response of osteoclasts to stimulation by osteoblastic
cells, increased resorption was accomplished predominantly
by an increase in the number of excavations formed with-
out significant change in the area of individual excavations
(data not shown), consistent with an increase in the propor-
tion of osteoclasts that were resorptive (9, 13). Moreover,
stimulation of bone resorption by hCD8-TRANCE was
quantitatively similar to that induced by the maximally active
concentration of PTH in cocultures of mature osteoclasts
with osteoblastic UMR 106 cells (Fig. 2); and PTH treat-
ment induced TRANCE mRNA expression in these cells
(data not shown). Moreover, PTH and hCD8-TRANCE
showed no additive effect, suggesting that TRANCE alone
is sufficient to fully account for the stimulation of bone re-
sorption induced in mature osteoclasts by PTH.
The osteoblast-dependent ability of PTH to stimulate
osteoclastic bone resorption was abrogated by soluble
TRANCE-R–Fc fusion protein (TR-Fc) (Fig. 3). In addi-
tion, a high level of TRANCE-R mRNA was detected in
mature osteoclasts (data not shown). This not only supports
the view that TRANCE stimulates the differentiation (6)
and activation of osteoclasts, but also provides evidence that,
similar to its action on dendritic cells (3, 4), TRANCE-R
is likely to be a receptor for signal transduction for activa-
tion of the osteoclast and its survival. In neither of the two
coculture systems did TR-Fc suppress bone resorption be-
low the basal levels of resorptive activity demonstrated by
osteoclasts in unstimulated cultures. This suggests that stim-
ulated bone resorption was inhibited through neutralization
Figure 1. An osteoclast photographed 30 (A) and 1 (B) min before, and
30 (C) and 60 (D) min after addition of hCD8-TRANCE to culture (100
ng/ml). Bar 5 2 mm. E, spread area of osteoclasts after incubation for 1 h
with or without hM-CSF (5 ng/ml) or hCD8-TRANCE (CD8-T; 100
ng/ml). F, number of TRAP-positive multinuclear cells (MNC) present
on coverslips in cultures of osteoclasts disaggregated from rat bone and in-
cubated for 24 h in M-CSF (5 ng/ml) or hCD8-TRANCE (12 cultures
per variable). Number of osteoclasts remaining after 24 h in hCD8-
TRANCE (1,000 ng/ml) and M-CSF did not differ significantly from
number present on coverslips incubated for 1 h. *P , 0.05 versus control
(Student’s t test).
Figure 2. Bone resorption by osteoclasts freshly isolated from neonatal
rat bones and incubated for 24 h on bone slices without (A) or with (B)
UMR 106 cells. A, osteoclasts incubated with M-CSF (5 ng/ml) with or
without PTH (0.1 U/ml) or hCD8-TRANCE. B, osteoclasts incubated
with hCD8-TRANCE (100 ng/ml) and/or PTH (0.1 U/ml) and/or
M-CSF (5 ng/ml). n 5 12 cultures per variable. *P , 0.05 versus control.
Number of TRAP-positive cells present after incubation did not differ
significantly between groups (range of means: A, 11.5–14.7; B, 17.8–
20.8). CD8-T, hCD8-TRANCE. 
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of TRANCE, rather than through induction (e.g., via re-
verse signaling by receptor-bound TRANCE, as can occur
in some members of this ligand family; references 14–17) of
osteoclast-inhibitory activity in osteoblastic cells. OPG also
neutralized the ability of both hCD8-TRANCE (Fig. 3)
and osteoblastic cells (Fig. 4) to stimulate bone resorption by
mature osteoclasts. Thus, OPG inhibits bone resorption
not only through inhibition of osteoclast formation (6, 7,
18), but also through suppression of osteoblast-stimulated
bone resorption by mature osteoclasts.
TRANCE thus appears to be both necessary and suffi-
cient to account for the ability of osteoblastic cells to stim-
ulate mature osteoclasts. Although osteoclast-stimulating
activity has on occasion been detected in culture superna-
tants from osteoblastic cells (19–23), it has also frequently
been detectable only when osteoblasts are cocultured with
osteoclasts (11, 24–26). It may be that, like some other
members of this family of ligands, TRANCE exists physio-
logically as membrane-expressed and soluble forms (27,
28). However, the relatively high concentrations of hCD8-
TRANCE that were required for activity suggests that, like
M-CSF (29), the ligand is normally presented to osteoclasts
on the surface of osteoblastic cells. It is also likely that un-
der some circumstances any TRANCE that is released by
osteoblastic cells will be neutralized by OPG, which is also
expressed by bone cells (6, 18). These and other potential
interactions are now amenable to analysis. The actions of
TRANCE on mature osteoclasts make this system of
ligand, receptor, and decoy receptor seem likely to be cru-
cial to the local regulation of osteoclastic localization, sur-
vival, and resorptive activity on bone surfaces, and thus to
our understanding of the mechanisms by which the intricate
and dynamic patterns of resorptive activity that occur during
skeletal morphogenesis and restructuring are regulated.
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Figure 3. Bone resorption by os-
teoclasts freshly isolated from neonatal
rat bones and incubated for 24 h on
bone slices with calvarial cells (A) or
UMR 106 cells (B), or alone (C).
hCD8-TRANCE, 100 ng/ml; OPG,
100 ng/ml. n 5 12 cultures per variable.
*P , 0.05 versus all other groups (A and
C) or versus PTH 0 and TR-Fc 2,000
ng/ml. CD8-T, hCD8-TRANCE; TR-
Fc, TRANCE-R- IgG1 fusion protein.
Figure 4. (A) Bone resorption by mature osteoclasts incubated for 18 h
on bone slices with calvarial cells (CC oc) or UMR 106 cells (UMR oc) in
the presence and absence of PTH (0.1 U/ml), 1,25(OH)2vitamin D3
(1028 M), and/or OPG (100 ng/ml). n 5 12 cultures per variable. *P , 0.01
versus all other groups (Student’s t test). (B) Bone resorption by mature os-
teoclasts disaggregated from neonatal rat long bones and incubated for 18 h
on bone slices alone (oc) or with added osteoblastic UMR 106 cells (UMR
oc). At no concentration did OPG significantly stimulate bone resorption.
Significant suppression of bone resorption by OPG (*P , 0.01 versus
O1PTH group) occurred at 100 ng/ml. n 5 12 cultures per variable. 
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